GoAI
Get started
Xuanzhubio-b logo

Xuanzhubio-b

2575.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

HK$10.30

−HK$0.76 · -6.87%

Aug 24, 1:36 PM HKT

2575.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include Core- KBP-3571, developed for treating duodenal ulcers; XZP-3287, a CDK4/6 inhibitor aimed at advanced HR+/HER2 breast cancer; and XZP-3621, intended as a first-line therapy for patients suffering from anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer. Its development pipeline further encompasses KM501, a pioneering HER2/HER2 bispecific antibody drug conjugate currently in Phase I clinical trials, alongside KM602, another anti-tumor agent also undergoing Phase I evaluation. Other investigational assets include XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 (PARP1) inhibitor; XZP-6924, which targets ubiquitin-specific protease 1 (USP1); XZB-0004, an oral small molecule anexelekto inhibitor; and XZP-6877, a DNA-dependent protein kinase inhibitor. The portfolio also features NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroidal farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor. Founded in 2008 and headquartered in Beijing, China, Xuanzhu Biopharmaceutical Co., Ltd. operates as a subsidiary of Sihuan Pharm.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CN
CEO
Yanjun Xu
Listed since
Oct 15, 2025
Employees
342

Market position

Day range

Current HK$10.30

52-week range

Current HK$10.30

Open
HK$11.50
Previous close
HK$11.06
Volume
194.5K
0.12× average
Average volume
1.67M
Average daily volume
Market cap
5.33B HKD
Beta
0.59
Market reference 1
50-day average
HK$13.208
-22.02% below average
200-day average
HK$40.1778
-74.36% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
35.75B HKD
P/E (TTM)
-20.2×
P/B (TTM)
3.5×
P/S (TTM)
95.01×
EV / EBITDA
-162.1×
Earnings yield
-0.73%
Free cash flow yield
-0.61%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
38.82%
Operating margin
-450.85%
Net margin
-474.21%
Return on equity
-17.45%
Return on assets
-14.57%
Return on invested capital
-16.01%

Financial health

Debt / equity
0×
Current ratio
3.75×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends116980%-350783%-818547%-1286310%Gross margin, FY2023: -110848.08%Gross margin, FY2024: -38.61%Gross margin, FY2025: 38.82%Operating margin, FY2023: -1169368.85%Operating margin, FY2024: -1873.40%Operating margin, FY2025: -450.85%Net margin, FY2023: -1036451.15%Net margin, FY2024: -1848.97%Net margin, FY2025: -474.21%FY2022FY2023FY2024FY2025
Gross margin FY2023 -110848.08%. Gross margin FY2024 -38.61%. Gross margin FY2025 38.82%. Operating margin FY2023 -1169368.85%. Operating margin FY2024 -1873.40%. Operating margin FY2025 -450.85%. Net margin FY2023 -1036451.15%. Net margin FY2024 -1848.97%. Net margin FY2025 -474.21%.

Income trends

Revenue

56.15M HKD+72.08%

Operating income

−253.14M HKD+58.59%

Net income

−266.26M HKD+55.87%
Income trends across reported periods122.89M HKD−144.08M HKD−411.04M HKD−678.01M HKDRevenue, FY2023: 32.04K HKDRevenue, FY2024: 32.63M HKDRevenue, FY2025: 56.15M HKDOperating income, FY2022: −580.24M HKDOperating income, FY2023: −374.71M HKDOperating income, FY2024: −611.27M HKDOperating income, FY2025: −253.14M HKDNet income, FY2022: −595.7M HKDNet income, FY2023: −332.12M HKDNet income, FY2024: −603.29M HKDNet income, FY2025: −266.26M HKDFY2022FY2023FY2024FY2025
Revenue FY2023 32.04K HKD. Revenue FY2024 32.63M HKD. Revenue FY2025 56.15M HKD. Operating income FY2022 −580.24M HKD. Operating income FY2023 −374.71M HKD. Operating income FY2024 −611.27M HKD. Operating income FY2025 −253.14M HKD. Net income FY2022 −595.7M HKD. Net income FY2023 −332.12M HKD. Net income FY2024 −603.29M HKD. Net income FY2025 −266.26M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022
Revenue56.15M HKD32.63M HKD32.04K HKD—
Cost of goods sold34.35M HKD45.23M HKD35.55M HKD30.16M HKD
Gross profit21.8M HKD−12.6M HKD−35.52M HKD−30.16M HKD
Research and development120.3M HKD180.92M HKD238.74M HKD444.94M HKD
Selling, general, and administrative146.34M HKD413.01M HKD95.61M HKD100.41M HKD
Operating expenses274.94M HKD598.67M HKD339.19M HKD550.08M HKD
Interest income7.37M HKD7.19M HKD15.93M HKD27.62M HKD
Interest expense134.48K HKD329.6K HKD1.29M HKD1.76M HKD
Depreciation and amortization32.59M HKD36.6M HKD35.54M HKD30.16M HKD
Operating income−253.14M HKD−611.27M HKD−374.71M HKD−580.24M HKD
Net income−266.26M HKD−603.29M HKD−332.12M HKD−595.7M HKD

Company facts updated Aug 24, 2026.

2575.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.8

-3.89%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.74

-3.03%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$222.4

-2.46%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.22

-5.62%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.2

-2.15%

ETFs holding 2575.HK

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P China ETF logoState Street SPDR S&P China ETFGXC
Market value
10.61K
Weight
0.00%
AUM
474.65M USD
Expense ratio
0.59%
Price / 1D
$91.50+0.51%

Continue in GoAI

Research 2575.HK

research.disclaimer